Latest News

View All Recent News »

Alimera Sciences' ILUVIEN® Receives Marketing Authorization in Finland and Luxembourg

January 26, 2015 -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that marketing authorization has been granted by the...

Read More »

Alimera Sciences Announces First Sale of ILUVIEN® in Portugal

January 14, 2015 -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals today announced that the first unit of ILUVIEN® has been sold in...

Read More »

Alimera Sciences Added to NASDAQ Biotechnology Index

December 16, 2014 -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that it has been added to the NASDAQ Biotechnology Index...

Read More »